|
 |
Hypertension
2009 - PI – Ronald Brazg, MD (Phase IV)
A Prospective, Open-Label Titration Study to Evaluate the Efficacy and Safety of An Investigational Medication in Multiple Subgroups of Hypertensive Subjects who are Non-Responders to Anti-Hypertensive Monotherapy.
2009 –PI – Leslie Klaff, MD, Ph.D (Phase IV)
An 8-Week Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients with Stage 2 Hypertension
2008 –PI – Ronald Brazg, MD (Phase IIb)
A Worldwide, Multicenter, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of An Investigational Medication When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension
2007 PI - Allen Sussman, MD (Phase III)
An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the
Safety and Tolerability of An Investigational Medication in Subjects with Essential Hypertension
2007 PI - Allen Sussman, MD (Phase III)
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of An Investigational Medication When Co-Administered with Amlodipine 5 mg in Subjects with Essential Hypertension.
2006- PI – Leslie Klaff, MD, Ph. D (Phase II)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects with Mild to Moderate Uncomplicated Essential Hypertension
2006- PI – Allen Sussman, MD (Phase III)
An 8-week, multicenter, randomized, double-blinded, parallel-group study to evaluate the efficacy and safety of the combination of Valsartan/HCTZ/Amlodipine compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in patients with moderate to severe hypertension
2005 – PI – Allen Sussman, MD (Phase IV)
A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing an investigational medication to ramipril with optional addition of hydrochlorothiazide, followed by a 4 week double-blind, randomized, placebo-controlled withdrawal in patients with essential hypertension.
2005 –PI – Leslie Klaff, MD, Ph. D. (Phase IV)
A Randomized, Double-Blind, Parallel-Filter Study to Evaluate the Antihypertensive Efficacy and Safety of an investigational medication Combination as Compared to an investigational medication in Patients with Essential Hypertension.
2002 –PI – Ronald Brazg, MD (Phase IV)
A Multicenter, Randomized, Double-Blind, Parallel Group Study Comparing the Safety and Efficacy of Lotrel versus Amlodipine in the treatment of Moderate to Severe Hypertension.
2001 PI - Leslie Klaff, MD
A Randomized, Double-Blind Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitis
2000 PI - Ronald Brazg, MD
A Randomized, Double-Blind Safety and Efficacy Study of Two Approved Antihypertensive Medications as First-Line Therapy After 6 Weeks in Patients With Severe Hypertension
2000 PI - Ronald Brazg, MD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9-Week, Dose Ranging Study of An Investigational Medication in the Treatment of Mild to Moderate Hypertension
1998 PI - Ronald Brazg, MD
A Multicenter, Randomized, Double-blind, Amlodipine and Placebo-Controlled, 10 Week Study of an Investigational Medication in the Treatment of Mild to Moderate Hypertension.
1997 PI - Allen Sussman, MD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Nine Week Study of an Investigational Medication in the Treatment of Mild to Moderate Hypertension
1997 PI - Allen Sussman, MD
A 12 week, Multicenter, Double-blind, Parallel, Positive-Controlled, Dose-Titration Study of an Investigational Medication compared to Enalapril in Patients with Severe Systolic Hypertension.
1997 PI - Allen Sussman, MD
A Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Parallel Dose-Ranging Study of an Investigational Medication in the Treatment of Mild to Moderate Hypertension.
1996 PI - Ronald Brazg, MD
A Fifty-Two Week, Multicenter, Double-blind, Placebo-Controlled, Parallel-Group Study to Compare the Effects of an Investigational Medication With Those of Placebo in Mild to Moderate Obese Patients Whose Hypertension is Controlled by an Angiotensin-Converting Enzyme Inhibitor, With or Without Concomitant Thiazide Diuretic Therapy.
1995-1996 PI - Allen Sussman, MD
A Randomized, Double-blind, Outpatient, Dose-Titration Trial of an Investigational Medication Versus Placebo in Patients with Essential Hypertension.
1992-1993 PI - Nancy L. Purcell, MD
Accupril Decision on Pharmacotherapy for Hypertension |
Phase I & Pharmacokinetic Unit